European Archives - Page 134 of 1169 - European Medical Journal

Which Treatment for Basal Cell Carcinoma is More Effective?

After five years, the probability of remaining free from treatment failure was 77.8% for patients who underwent superficial curettage.

FDA fast-tracks Boehringer's NSCLC drug review

The FDA has granted priority review to zongertinib for non-small cell lung cancer (NSCLC).

OCEAN(a)-DOSE Trial: New Data on Lipoprotein(a) and Oxidised Phospholipids

Olpasiran significantly lowers oxidized phospholipids on apolipoprotein B but has no impact on systemic inflammatory markers in cardiovascular disease.

New Study Explores ctDNA in Urothelial Cancer Treatment

Researchers aimed to establish a plasma ctDNA sequencing assay and evaluate its effectiveness in assessing tumour genetics and treatment response.

Rezivertinib Outperforms Gefitinib in NSCLC Treatment Study

A Phase III trial has shown that rezivertinib offers superior progression-free survival compared to gefitinib as a first-line treatment in EGFR-mutated locally advanced or metastatic non-small-cell lung cancer.

Combined Ultrasound Technique Reliable for Ruling Out N2 Disease in Patients with Lung Cancer

Study shows combined endobronchial ultrasound and endoscopic ultrasound (CUS) is a highly reliable tool for ruling out N2 disease in patients with PET-negative lung cancer.

Azithromycin Susceptibility of Oral Streptococci in Men Who Have Sex With Men

A recent randomised controlled trial came to the surprising conclusion that dual gonococcal treatment with azithromycin/ceftriaxone…

Self-Healing E-Skin Recovers in 10 Seconds, Transforming Biometric Wearables

A new self-healing E-Skin recovers within 10 seconds, enabling AI-assisted real-time health monitoring in extreme conditions.

Donal Brennan

Onc Now: Episode 11: The Obesity Cancer Connection

Donal Brennan shares insights on ovarian cancer surgery, obesity-related carcinogenesis, and innovations in patient care.

Daratumumab-Based Quadruplet Regimen Sets New Benchmark in Myeloma Treatment

A Phase III trial shows adding daratumumab to VRd enhances treatment response in transplant-ineligible multiple myeloma patients.